HALO - Halozyme Therapeutics licenses ENHANZE drug delivery technology to Chugai

Halozyme Therapeutics (NASDAQ:HALO) has granted Chugai a license to its ENHANZE drug delivery technology for use in an undisclosed target. The ENHANZE technology is based on the recombinant human hyaluronidase PH20 enzyme (rHuPH20). Terms of the collaboration and license agreement call for Chugai to make a $25M upfront payment, as well as up to $160M in milestone payments. Halozyme (HALO) is also entitled to royalties from sales of medicines developed by Chugai using ENHANZE. Check out why Seeking Alpha contributor Biologics  argues that Halozyme (HALO) is a strong buy.

For further details see:

Halozyme Therapeutics licenses ENHANZE drug delivery technology to Chugai